{"id":"W3133509869","doi":"10.1056/nejmoa1911149","title":"Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":841,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis","keywords":"Fulvestrant; Oncology; Medicine; Internal medicine; Interim analysis; Cancer; Breast cancer; Human Epidermal Growth Factor Receptor 2; Hormone receptor; Metastatic breast cancer; Clinical trial; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004543486,0.0002394642,0.0009082089,0.0002295462,0.00001855193,0.000005590348,0.0001414877,0.00006429252,0.0009287264],"category_scores_gemma":[0.00003901189,0.0001407357,0.00006365944,0.0002598855,0.0001098417,0.0002385224,0.00001374786,0.0005963921,0.000005831987],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002889163,"about_ca_system_score_gemma":0.0006336733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003726733,"about_ca_topic_score_gemma":0.0002646866,"domain_scores_codex":[0.9981186,0.00005779476,0.0005600994,0.0002048995,0.00071865,0.0003399672],"domain_scores_gemma":[0.9986746,0.0001387973,0.000368529,0.0002254396,0.0002431978,0.0003494432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05752128,0.0002046937,0.3611965,0.0003006533,0.0005125848,0.001574342,0.003811431,0.00626635,0.03679983,0.0003476434,0.0003744848,0.5310903],"study_design_scores_gemma":[0.3509834,0.00427553,0.5875906,0.005324875,0.0002584689,0.01023474,0.001062097,0.0001215096,0.0005122765,0.0006100159,0.03867001,0.0003565555],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9773268,0.003250249,0.0004762051,0.01682337,0.0008516035,0.0002809729,0.000007364144,0.0000174142,0.0009660087],"genre_scores_gemma":[0.9937384,0.000640539,0.0009623072,0.0008585639,0.002757485,0.000002808566,0.000003863818,0.00004065941,0.0009953774],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5307337,"threshold_uncertainty_score":0.9999846,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01125536094792389,"score_gpt":0.2819309661319838,"score_spread":0.2706756051840599,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}